Alpha Particles Take on Glioblastoma: Inside Alpha Tau's REGAIN Trial

JERUSALEM – November 12, 2026 – In the landscape of modern oncology, few diagnoses carry the devastating weight of recurrent glioblastoma. For decades, this aggressive brain cancer has earned a grim reputation, routinely outmaneuvering surgical resection, systemic chemotherapy, and traditional radiation. Yet, at the intersection of advanced physics and precision neurosurgery, a new therapeutic modality is emerging.

Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, is preparing to pull back the curtain on the latest interim data from its REGAIN trial. On Monday, November 16, 2026, the company will host an investor call and webcast to discuss the clinical progress of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) in patients with recurrent glioblastoma. The briefing follows a highly anticipated presentation at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia, signaling a critical juncture for a technology that aims to fundamentally alter how we treat intractable central nervous system malignancies.

For observers of the longevity economy and the future of patient experience, the REGAIN trial represents more than just a novel mechanism of action. It is a case study in how highly targeted, minimally invasive interventions can potentially extend survival while preserving the delicate neurological functions that define human quality of life.

Taming 'The Terminator' of Brain Tumors

Recurrent glioblastoma is often characterized by its relentless growth and resistance to salvage therapies. Once a patient exhausts the standard of care—which typically includes initial surgery, radiation, and chemotherapy—the options narrow drastically. Re-irradiation carries severe risks of cognitive damage and tissue necrosis, while systemic agents like bevacizumab offer only modest, temporary reprieves.

Alpha Tau’s approach pivots away from traditional beta or gamma radiation, utilizing the unique physical properties of alpha particles. The Alpha DaRT platform relies on intratumoral delivery of radium-224 impregnated sources. As the radium decays, it releases short-lived alpha-emitting daughters that disperse within the tumor. Alpha particles are heavy and carry immense energy, capable of causing irreparable double-strand DNA breaks in cancer cells. Crucially, however, they travel only a microscopic distance—fractions of a millimeter.

This short path length is the strategic linchpin of the therapy. It allows for a highly potent, conformal dose of radiation to obliterate the tumor while sparing the adjacent, healthy brain tissue.

Early signals from the REGAIN trial have captured the attention of the neuro-oncology community. Preliminary data from the first three patients treated in the trial, evaluated earlier this year, demonstrated a 100 percent local disease control rate. Furthermore, two of the three patients achieved a complete disappearance of enhancing tumor lesions on serial MRI scans, translating to a 67 percent complete response rate based on standard neuro-oncology assessment criteria.

"In a disease state where objective response rates with most systemic therapies rarely reach double digits, seeing complete responses and local control in early human trials is a highly encouraging pattern," noted one clinical investigator familiar with the preliminary data.

While the safety profile remains a primary endpoint, early results have been manageable. One treatment-associated serious adverse event—a seizure accompanied by temporary paralysis—was reported but resolved following steroid administration. As of the last data cutoff, no patients had experienced local or distant recurrence, nor residual symptoms from the procedure itself.

Precision Neurosurgery Meets Targeted Radiation

The biological elegance of alpha particles would be moot without a viable delivery mechanism, particularly in the brain. Historically, accessing deep-seated intracranial tumors required open craniotomy—a brutal, highly invasive procedure that pre-treated, fragile patients often cannot tolerate.

Alpha Tau has circumvented this barrier by engineering a specialized stereotactic delivery system. The Alpha DaRT sources are implanted via a minimally invasive burr-hole access point. By interfacing directly with standard, real-time neuronavigation platforms already present in modern surgical suites, neurosurgeons can achieve precise, image-guided placement of the radioactive seeds without opening the skull.

This procedural innovation democratizes access to high-dose localized radiation. It shifts the paradigm from a grueling open surgery to a streamlined, stereotactic intervention. For hospital systems, this means reduced operating room time, shorter intensive care stays, and a more manageable recovery trajectory for the patient.

The FDA has recognized the potential of this approach. In October 2026, the agency approved an Investigational Device Exemption (IDE) supplement, allowing Alpha Tau to double the REGAIN trial's enrollment from 10 to 20 U.S. patients. The expanded protocol also broadens the inclusion criteria to encompass patients with IDH-mutant grade 4 tumors.

Perhaps most significantly for the patient experience, the FDA expansion added progression-free survival as a secondary endpoint and introduced regular quality-of-life assessments. This regulatory nod underscores a growing industry consensus: extending life must be inextricably linked to preserving the patient's cognitive and physical autonomy.

The Strategic Pivot: Beyond Head and Neck

From a market perspective, Alpha Tau’s foray into neuro-oncology represents a high-stakes expansion. Founded in 2016 on technology developed at Tel Aviv University, the company has already secured regulatory marketing approvals in Japan for unresectable locally advanced or recurrent head and neck cancer, and in Israel for squamous cell carcinoma of the skin and oral cavity.

Transitioning from superficial or easily accessible solid tumors to the brain is a formidable leap. Yet, it is a calculated risk that could redefine the company's valuation and commercial trajectory. The recurrent glioblastoma market is a graveyard of failed therapeutics, meaning any technology that demonstrates durable efficacy and safety will command significant strategic value.

Financially, Alpha Tau appears positioned to weather the intensive research and development cycles required for intracranial indications. As of the first quarter of 2026, the company reported a solid cash runway, with $80.2 million in cash, cash equivalents, and short-term deposits. While R&D expenses have naturally increased to support expanding clinical activities—reaching $11.0 million in Q1 2026—the burn rate aligns with the aggressive scaling of its pivotal trials.

Biotech analysts have taken note of this momentum. Recent months have seen upgrades and increased price targets from major financial institutions, reflecting cautious optimism about the expanded REGAIN trial and the broader Alpha DaRT pipeline. Beyond glioblastoma, the company recently completed patient enrollment in its ReSTART pivotal U.S. trial for recurrent cutaneous squamous cell carcinoma, with top-line data expected by year-end, and is advancing a multicenter IMPACT pilot study in pancreatic cancer.

The upcoming November 16 investor call—featuring Alpha Tau CEO Uzi Sofer, Chief Medical Officer Robert Den, CFO Raphi Levy, and the trial's principal investigator—will serve as a critical barometer. As the executives unpack the latest SNO presentation data, the broader life sciences sector will be watching closely. If the interim safety and feasibility data continue to hold steady as the patient cohort expands, Alpha Tau may well be charting a new course through one of oncology's most unforgiving landscapes.